Day One Biopharmaceuticals, Inc. stock is up 10.7% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November.
Day One Biopharmaceuticals, Inc. develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor.